---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002078"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:00:32.540684+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aziyo Biologics reports record annual net sales of ~$49M, Q4 up 15-17% YoY

## Summary
- Preliminary Q4 2022 net sales of ~$12.5-12.7M, up 15-17% vs Q4 2021.
- Full year 2022 record net sales of ~$49.0-49.2M, up 3-4% YoY; up ~15-16% excluding $4.9M discontinued product.
- SimpliDerm and CanGaroo combined Q4 net sales expected to grow ~30% vs Q4 2021.
- Company raised $15.2M in gross proceeds from recent financings; awaits FDA clearance for CanGaroo RM.
- CEO cites strong team performance; full Q4 and FY results expected in early March 2023.

## SEC filing metadata
- accession: 0001104659-23-002078
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465923002078/0001104659-23-002078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465923002078/tm232674d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002078
- JSON: https://secwatch.observer/filing/0001104659-23-002078.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002078.txt

## Key facts
- Earnings Releases
  ELUTIA INC. reported fourth quarter ended December 31, 2022 results: revenue approximately $12.5-$12.7 million.
  - Period: fourth quarter ended December 31, 2022
  - Revenue: approximately $12.5-$12.7 million
  - Result: preliminary results
  source text: Anticipate fourth quarter 2022 net sales of approximately $12.5-$12.7 million, an increase of 15%-17% compared to the same prior year period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708527/000110465923002078/0001104659-23-002078-index.htm
- Earnings Releases
  ELUTIA INC. reported full year ended December 31, 2022 results: revenue approximately $49.0-$49.2 million.
  - Period: full year ended December 31, 2022
  - Revenue: approximately $49.0-$49.2 million
  - Result: preliminary results
  source text: Anticipate full year 2022 record net sales of approximately $49.0-$49.2 million, an increase of 3%-4% compared to the prior year and , after excluding 2021 sales of a discontinued product of $4.9 million, an increase of approximately 15%-16%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708527/000110465923002078/0001104659-23-002078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.